Novo Nordisk Caught Between FDA Tailwind and a Brutal Revenue Outlook
FDA proposal to curb cheap copycats boosts Novo Nordisk shares 4.8%, but pricing pressure, competition, and a grim…
Novo Nordisk’s AI Gambit Meets a Brutal Price War
Novo Nordisk partners with OpenAI to counter Eli Lilly’s tech edge while slashing prices in a fierce weight-loss…